Clinical studies have demonstrated that curcumin inhibits NLRP3 inflammasome activation via NF-κB-induced P2X7R signalling in macrophages (Kong et al., 2016), and apigenin significantly reduces the mRNA and protein expression of TMAO-induced NLRP3 (Yamagata et al., 2019), which suggests that TCM could potentially treat CRC by impacting the NLRP3 inflammasome, providing a potential pathway. The gene discussed is NFKB1; the disease is colorectal carcinoma.